A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.
Abhishek Chakraborti, MD
Admission rates for chronic obstructive pulmonary disease (COPD) exacerbations actually vary dramatically season-to-season, according to new findings which may help hospitals and response-care facilities better prepare for spiked demand.
A retrospective analysis presented at the CHEST 2019 Annual Meeting in New Orleans this week showed patients were most likely to be admitted—and even readmitted—to the hospital for COPD exacerbations in the months of January-March (Q1), when compared to all 4 quarters (Qs) of the calendar year.
Investigators, led by Abhishek Chakraborti, MD, of the Brookdale Hospital and Medical Center in Brooklyn, assessed adult COPD patient and acute exacerbation data from the 2016 National Inpatient Sample and National Inpatient Database. Primary outcome was 30-day all-cause readmission, and secondary outcomes included in-hospital mortality, and cumulative resource utilization (as per length of stay, hospital costs, and charges).
Chakraborti and colleagues noted current projections of costs due to COPD—which affects 6% of the population—show it increasing to $49 billion annually in the US by 2020.
“Looking toward the future, intelligent redistribution of resources will be needed to continue to meet the needs of patients with COPD in an already overburdened health care system,” Chakraborti said in a statement.
The team had observed a population of 530,229 patients, with 58% being female and the mean age being 68 years old. The greatest proportion of hospital admissions occurred in Q1 (33.69%), as did the rate of readmissions compared to other quarters (Q2-aOR, 0.93; P <.01; Q4-aOR, 0.95; P <.01).
Additionally, patients admitted in Q1 also had the greatest mortality rate compared to each other quarter. Investigators noted the strain of healthcare resources in Q1 was compounded by a greater length of stay compared to the quarters—while total hospitalization costs and charges were comparable among the first 3 quarters.
Michelle Cao, MD, a member of the American College of Chest Physicians Scientific Presentations and Awards Committee and Clinical Associate Professor at Stanford University, California, commented the study calls several questions into action which could help improve morbidity, mortality, and economic burdens due to COPD.
“It is important to identify factors that contribute to increased rates of COPD exacerbations during the winter months, possible biomarkers, patterns of COPD exacerbations, specific phenotypes that may identify those who are more susceptible to exacerbations during Q1 season and, of course, preventive interventions,” Cao said in a statement.
The investigators concluded the greater rate of admissions during the coldest months of the year was also associated with greater mortality rates, and overall burden on healthcare resources.
“Intensification of preventive treatments in the first quarter of the year should impact overall mortality and readmission rates while alleviating some of the strain on health care resources,” Chakraborti said.
The study, “Seasonal Variations in Outcomes and Costs for COPD,” was presented at CHEST 2019.